DEL_Basilea Pharmaceutica ((DEL_0QNA)), Basilea Pharmaceutica ((CH:BSLN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix in treating invasive mold infections, a significant health concern due to its high mortality rate and limited treatment options.
Intervention/Treatment: The study tests fosmanogepix, administered either intravenously or orally, against standard antifungal treatments. Fosmanogepix is intended to treat invasive mold infections, offering a potentially more effective alternative to current therapies.
Study Design: This open-label, randomized study involves two cohorts: one receiving fosmanogepix and the other receiving standard antifungal therapy. The primary goal is to assess all-cause mortality by Day 42, with no masking involved, ensuring transparency in treatment effects.
Study Timeline: The study began in July 2025, with primary completion expected within eight months. The latest update was in July 2025, indicating ongoing recruitment and progress.
Market Implications: The success of fosmanogepix could significantly impact Basilea Pharmaceutica’s stock, enhancing investor confidence and positioning the company as a leader in antifungal treatments. This development is crucial given the limited competition in the invasive mold infection treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.